Pharmaceutics, Free Full-Text

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914, that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood–brain barrier (BBB). Owing to restricted transport across the BBB, FDA-approved drugs for the CNS have been generally limited to lipid-soluble small molecules. Drugs that do not cross the BBB can be re-engineered for transport on endogenous BBB carrier-mediated transport and receptor-mediated transport systems, which were identified during the 1970s–1980s. By the 1990s, a multitude of brain drug delivery technologies emerged, including trans-cranial delivery, CSF delivery, BBB disruption, lipid carriers, prodrugs, stem cells, exosomes, nanoparticles, gene therapy, and biologics. The advantages and limitations of each of these brain drug delivery technologies are critically reviewed.

UK Journal of Pharmaceutical and Biosciences - Kindcongress

Overcoming Barriers to Pharma Market Access in Emerging Markets

Bioavailability and Bioequivalence Research Facility, University

Free Vector Pharmaceutical research isometric landing page

115 Empty Pharma Capsules Stock Photos - Free & Royalty-Free Stock

MPI Arabian Pharmaceutical industry 'Aziziya Sachet, madina sharif

Debranjan Datta - Associate Professor Pharmacology - late shri

Pharmaceutics September 2011 - Browse Articles

Wilson and Gisvold's textbook of organic medicinal and

Text book of Modern Pharmaceutics - For M. pharmacy syllabus

Pharmacy Related Text Medical Background Pharmacy Stock Vector